Bristol-Myers Squibb shares are trading lower after the company announced its CheckMate -459 study evaluating Opdivo did not reach its primary endpoint and announced plans to sell OTEZLA to help ease FTC concerns regarding its acquisition of Celgene.
Benzinga Newsdesk